Published in World J Surg on April 01, 2011
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (2014) 1.58
Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One (2014) 1.45
Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol (2012) 1.03
Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol (2014) 0.87
Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol (2013) 0.85
Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol (2011) 0.85
Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore) (2015) 0.83
Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol (2011) 0.82
A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) (2014) 0.81
Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One (2014) 0.81
Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) (2015) 0.81
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer (2015) 0.78
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
Comparison of liver resection and transplantation for Child-pugh A cirrhotic patient with very early hepatocellular carcinoma and portal hypertension. Pak J Med Sci (2014) 0.77
Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol (2015) 0.76
Impact of smoking habit on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med (2014) 0.75
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol (2016) 0.75
Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) (2013) 0.75
Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One (2017) 0.75
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer (1954) 12.77
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (2009) 3.42
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 2.56
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg (2009) 1.53
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A (2007) 1.41
Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol (2000) 1.30
Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology (2009) 1.29
Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology (1996) 1.28
Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg (2006) 1.20
Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol (2009) 1.17
A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer (2005) 1.16
Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int (2006) 1.15
Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol (2010) 1.12
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol (2006) 1.08
Viral hepatocarcinogenesis: from infection to cancer. Liver Int (2008) 1.06
Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int (2005) 1.06
Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer (2006) 1.02
Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. J Gastroenterol Hepatol (2007) 1.02
Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg (2007) 0.98
Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int (2010) 0.96
Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg (2007) 0.94
Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int (2008) 0.86
Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score. World J Surg (2009) 0.86
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol (2002) 4.47
Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol (2006) 4.38
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology (2009) 4.36
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (2009) 3.42
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 2.56
Retracted Aberrant methylation of Reprimo in human malignancies. Int J Cancer (2005) 2.13
Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol (2015) 2.09
Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int (2009) 2.09
miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res (2008) 2.09
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol (2003) 2.08
Mitochondrial genome instability and mtDNA depletion in human cancers. Ann N Y Acad Sci (2005) 1.97
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Biochemical predictors for absence of common bile duct stones in patients undergoing laparoscopic cholecystectomy. Surg Endosc (2007) 1.91
Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer (2006) 1.77
A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol (2010) 1.77
Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer (2011) 1.68
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 1.64
Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol (2004) 1.63
The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res (2009) 1.62
Retracted Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol (2002) 1.52
Characteristics of autoimmune hepatitis in Taiwan: the 11 years' experiences of a medical center. Zhonghua Yi Xue Za Zhi (Taipei) (2002) 1.45
Antisense thymidylate synthase electrogene transfer to increase uptake of radiolabeled iododeoxyuridine in a murine model. J Nucl Med (2004) 1.43
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene (2002) 1.43
Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. J Clin Gastroenterol (2009) 1.42
Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol (2010) 1.42
Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis. Medicine (Baltimore) (2014) 1.41
Clinical significance of AXL kinase family in gastric cancer. Anticancer Res (2002) 1.40
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer (2006) 1.40
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst (2005) 1.35
Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg (2003) 1.35
Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer (2010) 1.30
Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J Clin Invest (2013) 1.30
Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics (2011) 1.29
Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol (2011) 1.28
Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology (2013) 1.28
Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol (2009) 1.26
Does drainage fluid amylase reflect pancreatic leakage after pancreaticoduodenectomy? World J Surg (2003) 1.25
Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer (2010) 1.23
Irritable bowel syndrome and negative appendectomy: a prospective multivariable investigation. Gut (2007) 1.23
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology (2006) 1.22
Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg (2006) 1.20
Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology (2002) 1.15
Interval appendectomy after conservative treatment of an appendiceal mass. World J Surg (2006) 1.13
Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol (2009) 1.12
Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol (2010) 1.12
Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Photodermatol Photoimmunol Photomed (2006) 1.11
Comparison of the survival difference between AJCC 6th and 7th editions for gastric cancer patients. World J Surg (2011) 1.11
Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res (2006) 1.10
Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol (2004) 1.09
Initial experience of robotic gastrectomy and comparison with open and laparoscopic gastrectomy for gastric cancer. J Gastrointest Surg (2012) 1.08
Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol (2004) 1.08
Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int (2005) 1.06
Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg (2004) 1.06
Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol (2002) 1.05
The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS One (2013) 1.05
Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery (2012) 1.04
Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene (2004) 1.04
Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol (2003) 1.04
Complications following D3 gastrectomy: post hoc analysis of a randomized trial. World J Surg (2006) 1.03
Multiple primary cancers in patients with gastric cancer. Hepatogastroenterology (2006) 1.02
SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett (2009) 1.02
Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl (2006) 1.02
Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) (2015) 1.01
Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology (2002) 1.01
Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer (2012) 1.01
Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma. Am J Gastroenterol (2003) 1.00
Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg (2012) 1.00
The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol (2007) 1.00
Is pancreaticoduodenectomy justified for chronic pancreatitis masquerading as periampullary tumor? Hepatogastroenterology (2003) 1.00
Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery (2009) 1.00